vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and SLM Corp (SLM). Click either name above to swap in a different company.

SLM Corp is the larger business by last-quarter revenue ($560.0M vs $406.6M, roughly 1.4× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 55.0%, a 5.5% gap on every dollar of revenue. Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 22.7%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Nikon SLM Solutions AG, headquartered in Lübeck, Germany, is a manufacturer of 3D metal printers listed on the stock market and co-owner of the word mark SLM. The shares of SLM Solutions Group AG have been listed in Prime Standard of the Frankfurt Stock Exchange since May 9, 2014.

BCRX vs SLM — Head-to-Head

Bigger by revenue
SLM
SLM
1.4× larger
SLM
$560.0M
$406.6M
BCRX
Higher net margin
BCRX
BCRX
5.5% more per $
BCRX
60.5%
55.0%
SLM
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
22.7%
SLM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
SLM
SLM
Revenue
$406.6M
$560.0M
Net Profit
$245.8M
$308.0M
Gross Margin
97.7%
Operating Margin
64.0%
69.6%
Net Margin
60.5%
55.0%
Revenue YoY
209.1%
Net Profit YoY
1017.5%
1.0%
EPS (diluted)
$1.13
$1.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
SLM
SLM
Q1 26
$560.0M
Q4 25
$406.6M
$377.1M
Q3 25
$159.4M
$373.0M
Q2 25
$163.4M
$376.8M
Q1 25
$145.5M
$375.0M
Q4 24
$131.5M
$362.2M
Q3 24
$117.1M
$359.4M
Q2 24
$109.3M
$372.2M
Net Profit
BCRX
BCRX
SLM
SLM
Q1 26
$308.0M
Q4 25
$245.8M
$233.2M
Q3 25
$12.9M
$135.8M
Q2 25
$5.1M
$71.3M
Q1 25
$32.0K
$304.5M
Q4 24
$-26.8M
$111.6M
Q3 24
$-14.0M
$-45.2M
Q2 24
$-12.7M
$252.0M
Gross Margin
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
SLM
SLM
Q1 26
69.6%
Q4 25
64.0%
83.8%
Q3 25
18.6%
49.8%
Q2 25
18.2%
23.3%
Q1 25
14.6%
Q4 24
-3.4%
36.5%
Q3 24
6.6%
-16.6%
Q2 24
8.0%
91.0%
Net Margin
BCRX
BCRX
SLM
SLM
Q1 26
55.0%
Q4 25
60.5%
61.8%
Q3 25
8.1%
36.4%
Q2 25
3.1%
18.9%
Q1 25
0.0%
81.2%
Q4 24
-20.4%
30.8%
Q3 24
-12.0%
-12.6%
Q2 24
-11.6%
67.7%
EPS (diluted)
BCRX
BCRX
SLM
SLM
Q1 26
$1.54
Q4 25
$1.13
$1.11
Q3 25
$0.06
$0.63
Q2 25
$0.02
$0.32
Q1 25
$0.00
$1.40
Q4 24
$-0.13
$0.53
Q3 24
$-0.07
$-0.23
Q2 24
$-0.06
$1.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
SLM
SLM
Cash + ST InvestmentsLiquidity on hand
$274.7M
$5.2B
Total DebtLower is stronger
$6.2B
Stockholders' EquityBook value
$-119.2M
$2.4B
Total Assets
$514.2M
$29.4B
Debt / EquityLower = less leverage
2.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
SLM
SLM
Q1 26
$5.2B
Q4 25
$274.7M
$4.2B
Q3 25
$212.9M
$3.5B
Q2 25
$260.0M
$4.1B
Q1 25
$295.1M
$3.7B
Q4 24
$320.9M
$4.7B
Q3 24
$96.8M
$4.5B
Q2 24
$78.4M
$5.3B
Total Debt
BCRX
BCRX
SLM
SLM
Q1 26
$6.2B
Q4 25
$5.4B
Q3 25
$6.8B
Q2 25
$6.4B
Q1 25
$6.1B
Q4 24
$6.4B
Q3 24
$6.0B
Q2 24
$5.4B
Stockholders' Equity
BCRX
BCRX
SLM
SLM
Q1 26
$2.4B
Q4 25
$-119.2M
$2.5B
Q3 25
$-387.9M
$2.3B
Q2 25
$-421.6M
$2.4B
Q1 25
$-451.9M
$2.4B
Q4 24
$-475.9M
$2.2B
Q3 24
$-468.6M
$2.1B
Q2 24
$-475.6M
$2.3B
Total Assets
BCRX
BCRX
SLM
SLM
Q1 26
$29.4B
Q4 25
$514.2M
$29.7B
Q3 25
$446.4M
$29.6B
Q2 25
$457.2M
$29.6B
Q1 25
$480.0M
$28.9B
Q4 24
$490.4M
$30.1B
Q3 24
$491.3M
$30.0B
Q2 24
$472.4M
$28.8B
Debt / Equity
BCRX
BCRX
SLM
SLM
Q1 26
2.53×
Q4 25
2.19×
Q3 25
2.92×
Q2 25
2.70×
Q1 25
2.56×
Q4 24
2.98×
Q3 24
2.83×
Q2 24
2.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
SLM
SLM
Operating Cash FlowLast quarter
$292.0M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
$292.0M
$-64.5M
Q3 25
$41.6M
$-49.3M
Q2 25
$41.3M
$-138.7M
Q1 25
$-27.5M
$-146.1M
Q4 24
$-5.2M
$4.5M
Q3 24
$8.2M
$-113.4M
Q2 24
$-1.4M
$-143.8M
Free Cash Flow
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
SLM
SLM
Q1 26
Q4 25
1.19×
-0.28×
Q3 25
3.23×
-0.36×
Q2 25
8.12×
-1.95×
Q1 25
-859.91×
-0.48×
Q4 24
0.04×
Q3 24
Q2 24
-0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

Segment breakdown not available.

SLM
SLM

Net Interest Income$375.0M67%
Noninterest Income$185.0M33%

Related Comparisons